Wire · opportunities
FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant's Biz Strategy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya, a once-daily pill for dermatomyositis, a rare inflammatory disorder. The drug targets JAK1 and TYK2 proteins and is also being developed for three other rare immunological diseases with significant market potential.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 28 Aug 2026 and 29 Aug 2026.
◆ ◆ The Wire takeaway
You have a clearer path to enter rare disease treatment with targeted oral drugs like Lisraya gaining FDA approval. If you develop immunology drugs, this sets a precedent that should accelerate your regulatory planning and strategic partnerships.
◆ Coverage
3 sources · first reported 28 Aug 2026 · latest 29 Aug 2026
◆ Related on Wire
◆ Topics